Merck & Co Inc (MRK)

64.11
0.42 0.66
NYSE : Health Care
Prev Close 63.69
Open 63.81
Day Low/High 63.22 / 64.36
52 Wk Low/High 57.18 / 66.80
Volume 11.84M
Avg Volume 8.78M
Exchange NYSE
Shares Outstanding 2.74B
Market Cap 169.03B
EPS 1.40
P/E Ratio 39.36
Div & Yield 1.88 (3.00%)

Latest News

Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly

Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly

Merck vs. Eli Lilly.

Jim Cramer on Amazon, Tesla, Starbucks, Exxon, Chevron, American Airlines, Southwest Airlines, Merck and Tax Reform

Jim Cramer on Amazon, Tesla, Starbucks, Exxon, Chevron, American Airlines, Southwest Airlines, Merck and Tax Reform

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks.

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

What differentiated traders who were injured yesterday from those able to whether a sudden storm? Diversification.

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

U.S. stock futures fall as earnings from Amazon.com disappoint.

Supplement To Earnings News Release

Supplement To Earnings News Release

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2017.

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

The British pharma company suffers a setback with a lung-cancer drug it touted as a defense against a Pfizer takeover bid three years ago, and could be back in play.

REPEAT/AstraZeneca And Merck Establish Strategic Oncology Collaboration

REPEAT/AstraZeneca And Merck Establish Strategic Oncology Collaboration

AstraZeneca and Merck & Co., Inc.

AstraZeneca And Merck Establish Strategic Oncology Collaboration

AstraZeneca And Merck Establish Strategic Oncology Collaboration

AstraZeneca and Merck & Co., Inc.

Merck Announces Fourth-Quarter 2017 Dividend

Merck Announces Fourth-Quarter 2017 Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

Senate Votes to Approve Motion to Proceed on Health Care

Senate Votes to Approve Motion to Proceed on Health Care

Majority Leader Mitch McConnell needed 50 out of the 52 Senate Republicans to support him.

Senate Poised to Hold Procedural Vote on Health Care

Senate Poised to Hold Procedural Vote on Health Care

Majority Leader Mitch McConnell needs 50 out of the 52 Senate Republicans to support him.

Merck's Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint Of Non-Inferiority To Efavirenz, Both In Combination With Other Antiretroviral Agents, In Pivotal Phase 3 Trial For Treatment Of HIV-1 Infection

Merck's Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint Of Non-Inferiority To Efavirenz, Both In Combination With Other Antiretroviral Agents, In Pivotal Phase 3 Trial For Treatment Of HIV-1 Infection

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the DRIVE-AHEAD study, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and...

Merck Provides Update On Phase 3 Study Of KEYTRUDA® (pembrolizumab) Monotherapy In Patients With Previously Treated Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (HNSCC)

Merck Provides Update On Phase 3 Study Of KEYTRUDA® (pembrolizumab) Monotherapy In Patients With Previously Treated Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (HNSCC)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-040 trial investigating KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in previously...

FedEx Expects Financial Hit From Cyber Hack; Here's Who Else Who Could Feel Petya's Pain

FedEx Expects Financial Hit From Cyber Hack; Here's Who Else Who Could Feel Petya's Pain

FedEx joined snack-maker Mondelez among firms warning that the late-June hacks will affect their numbers.

Merck Announces U.S. Launch Of RENFLEXIS™ (infliximab-abda), A Biosimilar Of Remicade, For All Eligible Indications

Merck Announces U.S. Launch Of RENFLEXIS™ (infliximab-abda), A Biosimilar Of Remicade, For All Eligible Indications

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.

Merck Announces Week 96 Results From ONCEMRK, A Study Evaluating Once-Daily ISENTRESS® HD (raltegravir), In Combination With Other Antiretroviral Agents, For The Treatment Of HIV-1 Infection In Appropriate Patients

Merck Announces Week 96 Results From ONCEMRK, A Study Evaluating Once-Daily ISENTRESS® HD (raltegravir), In Combination With Other Antiretroviral Agents, For The Treatment Of HIV-1 Infection In Appropriate Patients

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of Week 96 results from the pivotal Phase 3 ONCEMRK study evaluating the efficacy and safety of ISENTRESS HD 1, a 1200 mg...

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

European Medicines Agency's CHMP Recommends Approval For Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Certain Patients With Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

European Medicines Agency's CHMP Recommends Approval For Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Certain Patients With Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...

Merck Announces U.S. FDA Grants Tentative Approval For LUSDUNA™ Nexvue™ (insulin Glargine Injection), A Follow-On Biologic Basal Insulin

Merck Announces U.S. FDA Grants Tentative Approval For LUSDUNA™ Nexvue™ (insulin Glargine Injection), A Follow-On Biologic Basal Insulin

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.

Merck Announces Presentations Of Clinical And Real-World Data At The Alzheimer's Association International Conference®

Merck Announces Presentations Of Clinical And Real-World Data At The Alzheimer's Association International Conference®

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of data at The Alzheimer's Association International Conference taking place in London, July 16-20, 2017.

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Upbeat guidance from Target inspires retail rally.

Merck Becomes #25 Most Shorted Dow Stock, Replacing Cisco Systems

The most recent short interest data has been released for the 06/30/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Cyber Attack Likely Cost Saint-Gobain 1% of First Half Sales

Cyber Attack Likely Cost Saint-Gobain 1% of First Half Sales

The French building firm probably lost about $230 million of sales from the cyber attack but said it might make some of them back in the third quarter.